GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lobe Sciences Ltd (XCNQ:LOBE) » Definitions » COGS-to-Revenue

Lobe Sciences (XCNQ:LOBE) COGS-to-Revenue : 0.00 (As of Feb. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Lobe Sciences COGS-to-Revenue?

Lobe Sciences's Cost of Goods Sold for the three months ended in Feb. 2024 was C$0.00 Mil. Its Revenue for the three months ended in Feb. 2024 was C$0.00 Mil.

Lobe Sciences's COGS to Revenue for the three months ended in Feb. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Lobe Sciences's Gross Margin % for the three months ended in Feb. 2024 was N/A%.


Lobe Sciences COGS-to-Revenue Historical Data

The historical data trend for Lobe Sciences's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lobe Sciences COGS-to-Revenue Chart

Lobe Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Aug19 Aug20 Aug21 Aug22 Aug23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.03

Lobe Sciences Quarterly Data
Dec18 Mar19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 Aug23 Nov23 Feb24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.01 -

Lobe Sciences COGS-to-Revenue Calculation

Lobe Sciences's COGS to Revenue for the fiscal year that ended in Aug. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.024 / 0.841
=0.03

Lobe Sciences's COGS to Revenue for the quarter that ended in Feb. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lobe Sciences  (XCNQ:LOBE) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Lobe Sciences's Gross Margin % for the three months ended in Feb. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Lobe Sciences COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lobe Sciences's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Lobe Sciences (XCNQ:LOBE) Business Description

Traded in Other Exchanges
Address
1199 West Hastings Street, Suite 1400, Vancouver, BC, CAN, V6E 3T5
Lobe Sciences Ltd is a technology and services company that provides real estate, financial, management, IP, and branding support for the development of transformational medicine. It is working to develop effective psilocybin-based therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder and devices for the efficient application of medications.

Lobe Sciences (XCNQ:LOBE) Headlines

No Headlines